|
Daniel's Biotech Briefing
BIO wrapped with debate over ultra-rare terminology and deal strategy, while Oblenio Bio secured $62 million to advance a trispecific autoimmune drug into first-in-human testing.
The top 10 stories from Thu Jun 25, 2026 07:05 AM to Fri Jun 26, 2026 07:06 AM
Generated June 26, 2026 at 7:06 AM
|
|
|
#1 Automating Clinical Decisions For Healthcare System Efficiencies Published 2026-06-26 A persistent gap remains between computer science research and clinical practice, limiting the translation of research advances into routine healthcare decision-making. Covered by: insights.citeline.com |
#2 The Golden Triangle and the gaps: Rethinking UK biotech Published 2026-06-25 An episode discusses the UK biotech ecosystem, focusing on the Golden Triangle’s changing role, scaling challenges, pension capital access, and maintaining global competitiveness. Covered by: biospace.com |
#3 Labs see rising demand for nitrosamine, topical performance and microbiome testing Published 2026-06-25 BioSpace conference discussions indicate sponsors are seeking earlier safety, quality, and performance data, driving increased demand for nitrosamine analysis, IVRT/IVPT testing, and microbiome database capabilities. Covered by: biospace.com |
#4 BIO Notebook: Big Pharmas Help With Entrances; Biotech M&A Offers Exits Published 2026-06-25 The final day of BIO featured discussions on early-stage biotech investment strategy, biotech M&A approaches, and a US FDA terminology debate over “ultra-rare.” Covered by: insights.citeline.com, insights.citeline.com |
#5 Days After Launch, Attunio Health Expands Precision Psychiatry Infrastructure with Quest Diagnostics and Getlabs Published 2026-06-25 Quest Diagnostics and Getlabs are strengthening Attunio’s AI-powered, biomarker-driven infrastructure by adding at-home blood and genetic testing, shortly after Attunio launched its precision psychiatry platform. Covered by: prnewswire.com |
#6 Autoimmune disease company Oblenio Bio clinches $62M in Series B Published 2026-06-25 Oblenio Bio raised $62 million in a Series B led by Pfizer Ventures to advance a trispecific T-cell engager for autoimmune diseases into a first-in-human study. Covered by: endpoints.news |
#7 Off-Target Effects Episode 7: Perceptive Advisors' Joe Edelman discusses how biotech investing has changed over his extensive career, and his philosophy on running an investment firm Published 2026-06-25 Joe Edelman of Perceptive Advisors says biotech markets have become more efficient since the 1990s, discusses single-asset versus pipeline firms and current M&A dynamics, and emphasizes unbiased investing. Covered by: biotechtv.com |
#8 How iBio aims to stand out in obesity by targeting ‘both sides of the equation’ for antibody discovery Published 2026-06-26 iBio says it reached a clinic after adopting an AI-powered discovery platform in 2022, and it describes the outcome as vindication. Covered by: fiercebiotech.com |
#9 Actio Biosciences has a precision medicine approach to rare diseases - promising preclinical data in a genetically defined epilepsy has them eagerly awaiting forthcoming clinical results Published 2026-06-26 Actio Biosciences’ CEO said limited access to medicines for rare genetic diseases drove its development efforts, and the company’s KCNT-1 program is in clinic after preclinical efficacy results. Covered by: biotechtv.com |
#10 Artiva's cell therapy approach to autoimmune conditions is unique because it is NK cell based, donor derived, and there is no engineering of the cells - they believe the benefit is already in the data Published 2026-06-26 Artiva’s CEO says its NK cell–based, donor-derived cell therapy for autoimmune conditions is intended for community administration and potential re-dosing, with a 350-patient randomized rheumatoid arthritis trial planned to start this year. Covered by: biotechtv.com |
